Leaving in the Corona-virus era, brings a lot of digital innovations including the first LBCT presentation virtually. The Victoria [1] study presented virtually at ACC 2020 and published simultaneously at NEJM presented the results of verisiguat, a novel oral soluble guanylate cyclase stimulator, that enhances the cyclic guanosine monophosphate (GMP) pathway by directly stimulating soluble guanylate cyclase through a binding site independent of nitric oxide, and it sensitizes soluble guanylate cyclase to endogenous nitric oxide by stabilizing nitric oxide binding to the binding site [2].

References

1. Armstrong PW., et al. “Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction”. New England Journal of Medicine 382.20 (2020): 1883-1893. 
2. Stasch J-P., et al. “Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease”. Circulation 123.20 (2011): 2263-2273.
3. McMurray JJV., et al. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction”. New England Journal of Medicine 381.21 (2019): 1995-2008.
4. McMurray JJ., et al. “Angiotensin-neprilysin inhibition versus enalapril in heart failure”. New England Journal of Medicine 371.11 (2014): 993-1004.

Citation

Citation: Dimitris J Richter. “Verisiguat: A New Kid in Town. But One Size does not Fit all Heart Failure". Acta Scientific Medical Sciences 4.6 (2020): 145-146.

Copyright

Copyright: © 2020 Dimitris J Richter. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.